Table 1.
Overview of some of the ongoing clinical trial performed in Malaria
| Agents | Class | Target name | Clinical Trial | Control | Study population | Dosage | Reference |
|---|---|---|---|---|---|---|---|
| Phenotypic assay | |||||||
| KAE609(cipargamin)* | Spiroindolone | Na + −ATPase 4 | Phase II | Not specified | Adult (>18 years and older) | 800 mg single dose for falciparum patients | NCT01836458 |
| MMV390048 | PfPI4K | Phosphatidylinositol-4 kinase | Phase I | Not specified | Healthy volunteers | 20 mg single dose as suspension for falciparum patients | NCT02281344 |
| KAF156* | PfCARL | Cyclic amine resistance locus inhibitor | Phase II | Not specified | Adult (>18 years) | 800 mg/day for 3 days and 800 mg single dose for uncomplicated falciparum and vivax | NCT01753323 |
| DSM265 | PfDHODH | Dihydroorotate dehydrogense | Phase II | Not specified | Adults (>18 years) | 400 mg single dose for uncomplicated falciparum and vivax | NCT02123290 |
| Synthetic Molecules | |||||||
| OZ277 + Piperaquine | PfATP6 | Pf-encoded sarcoplasmic endoplasmic reticulum calcium ATPase | Phase II-III | Dihydroartemisinin + piperaquine | Adult (>18 years) | Not specified | NCT02461186 |
| OZ439 + Piperaquine | endoperoxide ozonide | 1,2,4-trioxolane | Phase II-III | Not specified | 6 months to 70 years | OZ439 -800 mg single dose +1440 mg piperaquine for uncomplicated falciparum patients | NCT02083380 |
| Artemisone (BAY-44-9585) + Mefloquine | Artemisin derivative | Withdrawn | Artesunate | >16 years and older | Artemisone 4 mg/kg/day for 3 days, mefloquine 15 mg/kg/day for uncomplicated falciparum malaria | NCT00936767 | |
| Aminoquinoline scaffolds | |||||||
| Ferroquine | 4-aminoquinolines | Ferrocene − 4-aminoquinoline | Phase II Terminated | Placebo and Artesunate | >14 years and older | Ferroquine different doses with artesunate 4 mg/kg/day, once daily for 3 days vs placebo for uncomplicated falciparum malaria | NCT00988507 |
| AQ-13 | 4-aminoquinolines | Unknown | Phase II | Coartem | 18 years and older | Two (350 mg) capsules on day 1 and 2. One (350 mg) capsule on day 3 for for uncomplicated falciparum malaria | NCT01614964 |
| Tafenoquine | 8-aminoquinolines | Unknown | Phase III | Placebo, chloroquine, primaquine | 16 years and older | Tafenoquine 150 mg vs chloroquine different doses vs placebo for plasmodium vivax malaria | NCT02216123 |
| Antibiotics | |||||||
| Fosmidomycin | Streptomycin lavenduale | DOXP pathway | Phase IIa | unspecified | 1 year to 60 years | Fosmidomycin 450 mg twice daily + piperaquine 320 mg once daily for 3 days for uncomplicated falciparum malaria. | NCT02198807 |
| Other agents | |||||||
| Methylene blue + Primaquine | Phenothiazin dye | Unknown | Phase I | Healthy volunteers | 18 to 60 years | Primaquine 45 mg + methylene blue 600 mg single dose compared in patients with Normal G6PD vs G6PD deficiency | NCT01668433 |
Source: clinicaltrial.org, *Completed: waiting for results